https://media-us.eisai.com/ Eisai Newsroom https://media-us.eisai.com/2026-05-08-Update-on-FDA-Priority-Review-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-as-a-Starting-Dose-for-Early-Alzheimers-Disease Fri, 08 May 2026 02:30:00 -0400 https://media-us.eisai.com/2026-05-08-Update-on-FDA-Priority-Review-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-as-a-Starting-Dose-for-Early-Alzheimers-Disease https://media-us.eisai.com/2026-04-09-Eisai-to-Present-the-Latest-Data-on-Real-World-Treatment-with-Lecanemab-and-Supporting-a-Standardized-Framework-for-Treating-Early-Alzheimers-Disease-at-the-78th-American-Academy-of-Neurologys-Annual-Meeting Thu, 09 Apr 2026 08:00:00 -0400 https://media-us.eisai.com/2026-04-09-Eisai-to-Present-the-Latest-Data-on-Real-World-Treatment-with-Lecanemab-and-Supporting-a-Standardized-Framework-for-Treating-Early-Alzheimers-Disease-at-the-78th-American-Academy-of-Neurologys-Annual-Meeting https://media-us.eisai.com/2026-03-26-EISAI-TO-BEGIN-ENROLLING-PHASE-2-STUDY-IN-PATIENTS-WITH-NARCOLEPSY Thu, 26 Mar 2026 08:00:00 -0400 https://media-us.eisai.com/2026-03-26-EISAI-TO-BEGIN-ENROLLING-PHASE-2-STUDY-IN-PATIENTS-WITH-NARCOLEPSY https://media-us.eisai.com/2026-03-20-Results-from-Real-World,-Long-Term-Treatment-Persistence-with-LEQEMBI-R-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-TM-2026 Fri, 20 Mar 2026 12:05:00 -0400 https://media-us.eisai.com/2026-03-20-Results-from-Real-World,-Long-Term-Treatment-Persistence-with-LEQEMBI-R-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-TM-2026 https://media-us.eisai.com/2026-03-10-Eisai-to-Present-the-Latest-Data-on-Long-Term,-Real-World-Treatment-with-Lecanemab-at-the-AD-PD-TM-2026-Annual-Meeting Tue, 10 Mar 2026 19:30:00 -0400 https://media-us.eisai.com/2026-03-10-Eisai-to-Present-the-Latest-Data-on-Long-Term,-Real-World-Treatment-with-Lecanemab-at-the-AD-PD-TM-2026-Annual-Meeting https://media-us.eisai.com/2026-01-25-FDA-Accepts-LEQEMBI-R-IQLIKTM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-under-Priority-Review Sun, 25 Jan 2026 18:30:00 -0500 https://media-us.eisai.com/2026-01-25-FDA-Accepts-LEQEMBI-R-IQLIKTM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-under-Priority-Review https://media-us.eisai.com/2025-12-03-Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-R-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimers-Disease-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025 Wed, 03 Dec 2025 18:10:00 -0500 https://media-us.eisai.com/2025-12-03-Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-R-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimers-Disease-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025 https://media-us.eisai.com/2025-12-02-New-Data-Presented-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-R-lecanemab-irmb-on-Neurotoxic-A-Protofibrils-in-CSF Tue, 02 Dec 2025 16:40:00 -0500 https://media-us.eisai.com/2025-12-02-New-Data-Presented-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-R-lecanemab-irmb-on-Neurotoxic-A-Protofibrils-in-CSF https://media-us.eisai.com/2025-12-01-Eisai-Presents-New-Data-on-Anti-Tau-Antibody-Etalanetug-E2814-at-CTAD-2025 Mon, 01 Dec 2025 19:35:00 -0500 https://media-us.eisai.com/2025-12-01-Eisai-Presents-New-Data-on-Anti-Tau-Antibody-Etalanetug-E2814-at-CTAD-2025 https://media-us.eisai.com/2025-11-25-Eisai-Completes-Rolling-Submission-to-U-S-FDA-for-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-Under-Fast-Track-Status Tue, 25 Nov 2025 07:30:00 -0500 https://media-us.eisai.com/2025-11-25-Eisai-Completes-Rolling-Submission-to-U-S-FDA-for-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-Under-Fast-Track-Status https://media-us.eisai.com/2025-11-18-Eisai-to-Present-Data-on-Lecanemab-Continued-Treatment,-Subcutaneous-Initiation-Dosing,-and-Real-World-Experience-at-the-18th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference Tue, 18 Nov 2025 08:00:00 -0500 https://media-us.eisai.com/2025-11-18-Eisai-to-Present-Data-on-Lecanemab-Continued-Treatment,-Subcutaneous-Initiation-Dosing,-and-Real-World-Experience-at-the-18th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference https://media-us.eisai.com/2025-10-13-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Autoinjector-Named-to-TIMEs-Best-Inventions-of-2025 Mon, 13 Oct 2025 19:30:00 -0400 https://media-us.eisai.com/2025-10-13-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Autoinjector-Named-to-TIMEs-Best-Inventions-of-2025 https://media-us.eisai.com/2025-10-06-Eisai-and-Biogen-Announce-U-S-Availability-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease Mon, 06 Oct 2025 16:30:00 -0400 https://media-us.eisai.com/2025-10-06-Eisai-and-Biogen-Announce-U-S-Availability-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease https://media-us.eisai.com/2025-09-16-Anti-MTBR-microtubule-binding-region-Tau-Antibody-Etalanetug-Granted-FDA-Fast-Track-Designation Tue, 16 Sep 2025 19:31:00 -0400 https://media-us.eisai.com/2025-09-16-Anti-MTBR-microtubule-binding-region-Tau-Antibody-Etalanetug-Granted-FDA-Fast-Track-Designation https://media-us.eisai.com/2025-09-08-Eisai-Presents-Clinical-Study-Results-of-Novel-Orexin-Receptor-Agonist-E2086-for-Narcolepsy-at-World-Sleep-2025 Mon, 08 Sep 2025 00:01:00 -0400 https://media-us.eisai.com/2025-09-08-Eisai-Presents-Clinical-Study-Results-of-Novel-Orexin-Receptor-Agonist-E2086-for-Narcolepsy-at-World-Sleep-2025 https://media-us.eisai.com/2025-09-03-Eisai-to-Present-Latest-Data-on-Lemborexant-and-Novel-Orexin-Receptor-Agonist-E2086-at-The-World-Sleep-2025 Wed, 03 Sep 2025 19:30:00 -0400 https://media-us.eisai.com/2025-09-03-Eisai-to-Present-Latest-Data-on-Lemborexant-and-Novel-Orexin-Receptor-Agonist-E2086-at-The-World-Sleep-2025 https://media-us.eisai.com/2025-09-02-Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the-U-S-FDA-for-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-Under-Fast-Track-Status Tue, 02 Sep 2025 19:30:00 -0400 https://media-us.eisai.com/2025-09-02-Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the-U-S-FDA-for-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-Under-Fast-Track-Status https://media-us.eisai.com/2025-08-29-FDA-Approves-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease Fri, 29 Aug 2025 15:58:00 -0400 https://media-us.eisai.com/2025-08-29-FDA-Approves-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease https://media-us.eisai.com/2025-07-30-Two-Year-Real-World-Study-of-LEQEMBI-R-in-the-United-States-Presented-at-Alzheimers-Association-International-Conference-AAIC-2025 Wed, 30 Jul 2025 11:00:00 -0400 https://media-us.eisai.com/2025-07-30-Two-Year-Real-World-Study-of-LEQEMBI-R-in-the-United-States-Presented-at-Alzheimers-Association-International-Conference-AAIC-2025 https://media-us.eisai.com/2025-07-30-New-Data-Presented-at-AAIC-Demonstrates-Investigational-LEQEMBI-R-lecanemab-irmb-360-mg-Subcutaneous-Maintenance-Dosing-Could-Offer-a-New-Option-for-Ongoing-Treatment-of-Early-Alzheimers-Disease Wed, 30 Jul 2025 09:00:00 -0400 https://media-us.eisai.com/2025-07-30-New-Data-Presented-at-AAIC-Demonstrates-Investigational-LEQEMBI-R-lecanemab-irmb-360-mg-Subcutaneous-Maintenance-Dosing-Could-Offer-a-New-Option-for-Ongoing-Treatment-of-Early-Alzheimers-Disease https://media-us.eisai.com/2025-07-30-Early-Alzheimers-Patients-Continue-to-Benefit-from-Four-Years-of-LEQEMBI-R-lecanemab-irmb-Therapy-New-Clinical-Data-Presented-at-AAIC Wed, 30 Jul 2025 08:07:00 -0400 https://media-us.eisai.com/2025-07-30-Early-Alzheimers-Patients-Continue-to-Benefit-from-Four-Years-of-LEQEMBI-R-lecanemab-irmb-Therapy-New-Clinical-Data-Presented-at-AAIC https://media-us.eisai.com/2025-07-21-EISAI-TO-PRESENT-FOUR-YEAR-EFFICACY-AND-SAFETY-DATA-ON-CONTINUOUS-TREATMENT-WITH-LECANEMAB-AT-THE-ALZHEIMERS-ASSOCIATION-INTERNATIONAL-CONFERENCE-2025 Mon, 21 Jul 2025 19:30:00 -0400 https://media-us.eisai.com/2025-07-21-EISAI-TO-PRESENT-FOUR-YEAR-EFFICACY-AND-SAFETY-DATA-ON-CONTINUOUS-TREATMENT-WITH-LECANEMAB-AT-THE-ALZHEIMERS-ASSOCIATION-INTERNATIONAL-CONFERENCE-2025 https://media-us.eisai.com/2025-03-25-EISAI-TO-PRESENT-LECANEMAB-REAL-WORLD-EXPERIENCE-DATA-AND-FINDINGS-FROM-NEUROLOGY-PORTFOLIO-AT-THE-AMERICAN-ACADEMY-OF-NEUROLOGY-AAN-ANNUAL-MEETING Tue, 25 Mar 2025 07:30:00 -0400 https://media-us.eisai.com/2025-03-25-EISAI-TO-PRESENT-LECANEMAB-REAL-WORLD-EXPERIENCE-DATA-AND-FINDINGS-FROM-NEUROLOGY-PORTFOLIO-AT-THE-AMERICAN-ACADEMY-OF-NEUROLOGY-AAN-ANNUAL-MEETING https://media-us.eisai.com/2025-02-28-The-Committee-for-Medicinal-Products-for-Human-Use-CHMP-Reaffirms-Positive-Opinion-for-Lecanemab-in-Early-Alzheimers-Disease Fri, 28 Feb 2025 08:23:00 -0500 https://media-us.eisai.com/2025-02-28-The-Committee-for-Medicinal-Products-for-Human-Use-CHMP-Reaffirms-Positive-Opinion-for-Lecanemab-in-Early-Alzheimers-Disease https://media-us.eisai.com/2025-01-26-FDA-Approves-LEQEMBI-R-lecanemab-irmb-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease Sun, 26 Jan 2025 18:30:00 -0500 https://media-us.eisai.com/2025-01-26-FDA-Approves-LEQEMBI-R-lecanemab-irmb-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease